SG11201811405QA - Improved differentiation method - Google Patents

Improved differentiation method

Info

Publication number
SG11201811405QA
SG11201811405QA SG11201811405QA SG11201811405QA SG11201811405QA SG 11201811405Q A SG11201811405Q A SG 11201811405QA SG 11201811405Q A SG11201811405Q A SG 11201811405QA SG 11201811405Q A SG11201811405Q A SG 11201811405QA SG 11201811405Q A SG11201811405Q A SG 11201811405QA
Authority
SG
Singapore
Prior art keywords
international
methods
uppsalalaan
utrecht
pct
Prior art date
Application number
SG11201811405QA
Inventor
Johannes Carolus Clevers
Joep Beumer
Original Assignee
Koninklijke Nederlandse Akademie Van Wetenschappen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Nederlandse Akademie Van Wetenschappen filed Critical Koninklijke Nederlandse Akademie Van Wetenschappen
Publication of SG11201811405QA publication Critical patent/SG11201811405QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C12N5/068—Stem cells; Progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/220586 Al 28 December 2017 (28.12.2017) WIP0 I PCT (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) (74) International Patent Classification: (81) C12N 5/071 (2010.01) A61K 31/4427 (2006.01) International Application Number: PCT/EP2017/065101 International Filing Date: 20 June 2017 (20.06.2017) English Publication Language: English Priority Data: 1610748.4 20 June 2016 (20.06.2016) GB (84) Applicant: KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN [NL/NL]; c/o Hubrecht Institute, Uppsalalaan 8, 3584 Utrecht (NL). Inventors: CLEVERS, Johannes Carolus; Hubrecht In- stitute, Uppsalalaan 8, 3584 Utrecht (NL). BEUMER, Joep; Hubrecht Institute, Uppsalalaan 8, 3584 Utrecht (NL). Agent: GOODFELLOW, Hugh Robin et al.; Carpmaels & Ransford LLP, One Southampton Row, London WC1B 5HA (GB). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). — = = (54) (57) Title: IMPROVED DIFFERENTIATION R , , . E F t , So, V METHOD FIG. EGFRI „., D EGFR . 5A .3,7. fr , I 1 ; I ' ,2 - , . \"S. FRi rtl e, and = = = = = = = = = = = = = = 11 .4 GC kr) 0 ei ei IN 0 to N in enteroendocrine cells and medical uses relating to such methods. CHUALYZ uses of the cells and organoids obtained by said methods. The invention also relates to methods for modulating hormone expression : The invention relates to methods and media for differentiating cells, for example for obtaining enteroendocrine cells, C [Continued on next page] WO 2017/220586 Al MIDEDIM01101 DIDIRMEMEE11OI0111111011111111101111111111111111111 Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
SG11201811405QA 2016-06-20 2017-06-20 Improved differentiation method SG11201811405QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1610748.4A GB201610748D0 (en) 2016-06-20 2016-06-20 Improved diffrentation method
PCT/EP2017/065101 WO2017220586A1 (en) 2016-06-20 2017-06-20 Improved differentiation method

Publications (1)

Publication Number Publication Date
SG11201811405QA true SG11201811405QA (en) 2019-01-30

Family

ID=56895200

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811405QA SG11201811405QA (en) 2016-06-20 2017-06-20 Improved differentiation method

Country Status (13)

Country Link
US (1) US20210047618A1 (en)
EP (1) EP3472302A1 (en)
JP (2) JP7525263B2 (en)
KR (2) KR102478617B1 (en)
CN (1) CN109844098A (en)
AU (1) AU2017281406B2 (en)
BR (1) BR112018076554A2 (en)
CA (1) CA3030098A1 (en)
GB (1) GB201610748D0 (en)
IL (1) IL263854A (en)
MX (1) MX2018016258A (en)
SG (1) SG11201811405QA (en)
WO (1) WO2017220586A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
WO2013093812A2 (en) 2011-12-19 2013-06-27 Umc Utrecht Holding B.V. A rapid quantitative assay to measure cftr function in a primary intestinal culture model
US10597633B2 (en) 2014-05-16 2020-03-24 Koninklijke Nederlandse Akademie Van Wetenschappen Culture method for organoids
CN113249297A (en) 2014-05-28 2021-08-13 儿童医院医疗中心 Methods and systems for converting precursor cells to stomach tissue via directed differentiation
US11584916B2 (en) 2014-10-17 2023-02-21 Children's Hospital Medical Center Method of making in vivo human small intestine organoids from pluripotent stem cells
GB201421094D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
GB201421092D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
EP3452578B1 (en) 2016-05-05 2022-08-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
NZ753873A (en) 2016-12-05 2023-01-27 Children’S Hospital Medical Center Colonic organoids and methods of making and using same
CN110317775B (en) * 2018-03-30 2022-06-10 中国科学院分子细胞科学卓越创新中心 Culture medium for hepatocyte culture and liver organoid preparation
WO2019217493A2 (en) * 2018-05-07 2019-11-14 President And Fellows Of Harvard College Cell populations and gene expression associated with in vitro beta cell differentiation
JP7377486B2 (en) * 2018-09-10 2023-11-10 国立大学法人東京工業大学 Method for producing intestinal cells from pluripotent stem cells
KR20200065892A (en) 2018-11-30 2020-06-09 오가노이드사이언스 주식회사 A composition for bio transplanting of organoid
KR102133693B1 (en) * 2018-12-28 2020-07-13 서울대학교병원 Method for differentiating salivary gland stem cell to salivary gland tissue and pharmaceutical composition for treating or preventing xerostomia
CN111500525B (en) * 2019-01-30 2023-05-02 中国科学院广州生物医药与健康研究院 Composition and application thereof
ES2961154T3 (en) * 2019-02-19 2024-03-08 Miltenyi Biotec Bv & Co Kg Cell culture medium and method for the generation of epithelial organoids from epithelial stem cells
CN113423818A (en) * 2019-02-26 2021-09-21 北京大学 Compositions and methods for long term culture of hepatocytes
GB201906978D0 (en) 2019-05-17 2019-07-03 Koninklijke Nederlandse Akademie Van Wetenschappen Improved culture method using integrin agonist
WO2021055565A1 (en) * 2019-09-17 2021-03-25 The Trustees Of Indiana University Prolonged function of liver organoids as an in vitro model for the study of liver disease
US11629385B2 (en) 2019-11-22 2023-04-18 Tempus Labs, Inc. Tumor organoid culture compositions, systems, and methods
KR102232244B1 (en) * 2019-11-29 2021-03-24 고려대학교 산학협력단 A composition for enhancing efficiency of reprogramming of somatic cells into induced pluripotent stem cells comprising MHY1485 or a derivative thereof and method for enhancing efficiency of reprogramming using the same
WO2021113821A1 (en) 2019-12-05 2021-06-10 Tempus Labs, Inc. Systems and methods for high throughput drug screening
AU2020399785A1 (en) * 2019-12-12 2022-06-30 The Walter And Eliza Hall Institute Of Medical Research Organoid cultures
GB202004706D0 (en) 2020-03-31 2020-05-13 Koninklijke Nederlandse Akademie Van Wetenschappen Methods and tools for studying enteroendocrine cells
US11561178B2 (en) 2020-04-20 2023-01-24 Tempus Labs, Inc. Artificial fluorescent image systems and methods
WO2021254296A1 (en) * 2020-06-14 2021-12-23 浙江大学 Bioactive substance composition, serum-free culture medium comprising the composition, and uses thereof
US20220135950A1 (en) * 2020-11-03 2022-05-05 Korea Research Institute Of Bioscience And Biotechnology Human intestinal epithelium model and method for preparing same
CN113151152A (en) * 2021-05-11 2021-07-23 中国人民解放军军事科学院军事医学研究院 Culture method of mouse lung organoid and special culture solution thereof
WO2022241303A1 (en) * 2021-05-14 2022-11-17 University Of South Florida Composition and method for treating covid-19
CN113073080B (en) * 2021-06-03 2021-08-13 北京科途医学科技有限公司 Polymorphic rhabdomyosarcoma organoid and culture method, culture medium and application thereof
CN113403277B (en) * 2021-06-28 2023-05-16 山东省第二人民医院(山东省耳鼻喉医院、山东省耳鼻喉研究所) Method for separating FZD10 positive glial cells of inner ear
GB202109913D0 (en) * 2021-07-09 2021-08-25 Stichting Hubrecht Organoid Tech Organoid-derived monolayers and uses thereof
JPWO2023074648A1 (en) * 2021-10-25 2023-05-04
EP4423252A1 (en) * 2021-10-29 2024-09-04 Trailhead Biosystems Inc. Methods and compositions for generating human forebrain neural progenitor cells and for maturation thereof to parvalbumin+ interneurons
KR20240088578A (en) * 2022-11-24 2024-06-20 한국생명공학연구원 Xenogenic-free culture of intestinal stem cell on the thin film-coated surfaces
CN116478912A (en) 2023-06-07 2023-07-25 合肥工业大学 Culture medium for inducing directional differentiation of intestinal organoids of mice into enteroendocrine cells and application of culture medium

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5458112B2 (en) * 2009-02-03 2014-04-02 コーニンクレッカ ネザーランド アカデミー ヴァン ウェテンシャッペン Culture medium for epithelial stem cells and organoids containing the stem cells
EP2772534B1 (en) * 2011-10-27 2019-09-18 National University Corporation Tokyo Medical and Dental University Culturing colorectal epithelial stem cells and transplanting colorectal epithelium
SG11201506520TA (en) * 2013-02-18 2015-09-29 Univ Health Network Methods for generating hepatocytes and cholangiocytes from pluripotent stem cells
PT2970890T (en) * 2013-03-14 2020-04-24 Massachusetts Inst Technology Compositions and methods for epithelial stem cell expansion and culture
EP3160503B1 (en) 2014-06-26 2021-02-17 The Trustees of Columbia University in the City of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
JP2019506153A (en) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー Production of differentiated enteroendocrine cells and insulin-producing cells

Also Published As

Publication number Publication date
WO2017220586A1 (en) 2017-12-28
RU2018145539A3 (en) 2021-03-19
MX2018016258A (en) 2019-05-20
CN109844098A (en) 2019-06-04
KR102478617B1 (en) 2022-12-19
CA3030098A1 (en) 2017-12-28
GB201610748D0 (en) 2016-08-03
JP2019527068A (en) 2019-09-26
IL263854A (en) 2019-02-03
AU2017281406A1 (en) 2019-01-17
US20210047618A1 (en) 2021-02-18
KR20190028443A (en) 2019-03-18
BR112018076554A2 (en) 2019-04-02
JP2022068302A (en) 2022-05-09
JP7525263B2 (en) 2024-07-30
EP3472302A1 (en) 2019-04-24
KR20230004913A (en) 2023-01-06
AU2017281406B2 (en) 2022-07-14
RU2018145539A (en) 2020-07-21

Similar Documents

Publication Publication Date Title
SG11201811405QA (en) Improved differentiation method
SG11201806988UA (en) Improved differentiation method
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201810591VA (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201909949XA (en) Targeted immunotolerance
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201806758VA (en) Vcn enhancer compositions and methods of using the same
SG11201903928WA (en) Mesenchymal stem cells populations, their products, and use thereof
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201806639VA (en) New streptococcal proteases
SG11201806398YA (en) Optimized factor viii genes
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201805420SA (en) Antibodies and conjugates thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201907023UA (en) Method of reducing neutropenia
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201909303TA (en) Point of delivery cold slurry generation
SG11201908092RA (en) Anti-tigit antigen-binding proteins and methods of use thereof
SG11201906961UA (en) Polypeptide variants and uses thereof
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201808592PA (en) Method for selection of high m6p recombinant proteins